{"name":"BioDelivery Sciences International","slug":"biodelivery-sciences-international","ticker":"","exchange":"","domain":"","description":"BioDelivery Sciences International is a specialty pharmaceutical company focused on the development and commercialization of innovative oral, transmucosal, and injectable products that address significant unmet medical needs. The company has a diverse pipeline with several drugs in various stages of development, including BEMA Fentanyl and DFN-15 Active, both in Phase 3 trials.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":61985000,"revenueGrowth":395.5,"grossMargin":0,"rdSpend":0,"netIncome":84860000,"cash":324596000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-30","label":"Buprenorphine and naloxone Phase 3 readout (Opioid Use)","drug":"Buprenorphine and naloxone","drugSlug":"buprenorphine-and-naloxone","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BEMA™","genericName":"BEMA™","slug":"bema","indication":"Opioid-induced breakthrough pain (primary development indication)","status":"phase_3"},{"name":"DFN-15 Active","genericName":"DFN-15 Active","slug":"dfn-15-active","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"EN3409","genericName":"EN3409","slug":"en3409","indication":"Moderate to severe chronic pain","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Belbuca 600 µg","genericName":"Belbuca 600 µg","slug":"belbuca-600-g","indication":"Other","status":"phase_1"},{"name":"Buprenorphine and naloxone","genericName":"Buprenorphine and naloxone","slug":"buprenorphine-and-naloxone","indication":"Other","status":"discontinued"},{"name":"Oxycodone 60 mg","genericName":"Oxycodone 60 mg","slug":"oxycodone-60-mg","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BEMA Fentanyl","genericName":"BEMA Fentanyl","slug":"bema-fentanyl","indication":"Breakthrough pain in opioid-tolerant cancer patients","status":"phase_3"}]}],"pipeline":[{"name":"BEMA™","genericName":"BEMA™","slug":"bema","phase":"phase_3","mechanism":"BEMA is a buccal film delivery system that rapidly dissolves in the mouth to deliver active pharmaceutical ingredients through the oral mucosa for faster systemic absorption.","indications":["Opioid-induced breakthrough pain (primary development indication)","Acute pain management"],"catalyst":""},{"name":"BEMA Fentanyl","genericName":"BEMA Fentanyl","slug":"bema-fentanyl","phase":"phase_3","mechanism":"BEMA Fentanyl is a fentanyl formulation delivered via a buccal mucoadhesive patch that provides rapid opioid analgesia for breakthrough pain.","indications":["Breakthrough pain in opioid-tolerant cancer patients"],"catalyst":""},{"name":"Belbuca 600 µg","genericName":"Belbuca 600 µg","slug":"belbuca-600-g","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buprenorphine and naloxone","genericName":"Buprenorphine and naloxone","slug":"buprenorphine-and-naloxone","phase":"discontinued","mechanism":"12.1 Mechanism of Action Buprenorphine and naloxone sublingual tablet contains buprenorphine and naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.","indications":[],"catalyst":""},{"name":"DFN-15 Active","genericName":"DFN-15 Active","slug":"dfn-15-active","phase":"phase_3","mechanism":"DFN-15 is a buprenorphine sublingual tablet formulation designed to provide rapid onset and consistent opioid receptor agonism for pain management.","indications":["Moderate to severe acute pain"],"catalyst":""},{"name":"EN3409","genericName":"EN3409","slug":"en3409","phase":"phase_3","mechanism":"EN3409 is a buprenorphine formulation designed to provide sustained opioid receptor agonism with reduced abuse potential through a specialized delivery technology.","indications":["Moderate to severe chronic pain","Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"Oxycodone 60 mg","genericName":"Oxycodone 60 mg","slug":"oxycodone-60-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNbXhRS3Q5em5PVEwtMWtFQUtDZnRmQ1RGNkVWVHlMUm9QWUxpYkNjQWFQaENmVjU5Uk9CVmxONHJkcjJvZjRrVEM4dlQ2STBzMlN4Z2Y2aWR3Yk4tYTdjWm5fRVhIelNqSE5wblU3RnY4SWs5VVZKT1U2NFR1NUs5cEkxSXRVX3hzYkVB0gGQAUFVX3lxTE5tT3dHQ3lReWtZV3RQT1FOMTVWYVdZa0FOVzd4ZWVHSnd0bWx1RHhldVJUblM4NThuRTdHZ1NUMWhDaXhvOURETnVZTGE1Ql82a0hBZms1bVh1NEFXS01NaWFXdnhLN25sb1RESzlpeEdTM3h5Y0ZRSzMxRS11c2c1bEVuQVFCalM1Y3FwMy0xYg?oc=5","date":"2024-04-29","type":"pipeline","source":"Consulting.us","summary":"Santander Pharma Consulting launches in Durham - Consulting.us","headline":"Santander Pharma Consulting launches in Durham","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPN1YwQUZ5LTlMVENwWm5mSGh5a01QclVzV20xS0d5SElyTzEyaDBGUnkxbE94VWljVHpSWlAydXQ2VmZpSmlJaDhVMFVpU2ZIRUVkaEhGYUZEZTdmMXhYMk1uOTBFTEdXRmllQldmZEtBMjlwb0JmbVN4Q0tHRXVKZHFOM3o0MVRnbzZMdkUxN050YW8?oc=5","date":"2023-01-18","type":"pipeline","source":"citybiz","summary":"Corium Pharma Solutions Appoints Mark Sirgo As CEO - citybiz","headline":"Corium Pharma Solutions Appoints Mark Sirgo As CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQOE0wYVdnM3VvcF91TmM2UUphNHZWTVBEdExGdVhmSGZPRTJ1TlBRbElUTlBrbWlZMkh6ZlNzdWRvRU1KTFNiTjZBeVJyd3BPN0FNSl9EZXlBa1NBbDZqaXVReUNkck5Ud2wxN3kxdWdsMzBNSDFqQkN5azU5XzRSdi1wLVAyTHVsenZvWndIaXYyUzBhU0psY1N0YURCbTRjc0VGU253NHVVRGNWVWpJQUdtYU5GaGpq?oc=5","date":"2022-02-14","type":"deal","source":"Contract Pharma","summary":"Collegium Purchases BioDelivery Sciences International in All-Cash Deal - Contract Pharma","headline":"Collegium Purchases BioDelivery Sciences International in All-Cash Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOLW93akhXcllGQVFVN3Q0TnZWaUdhdEtEZGhFV0pnZWJoRi0xNjBxZERKYTM5eFpRYVFrUWR0NEQxMjZYdUFJRVQwQmRkM3owcnhRdUVHcGdXTHQyR0JsRndUeE0xYy0xa2JOcHRTRTY1SU9JNWd2SjZ5TWNzbkMwZDFnRV9Nbk81ZVVudUthUkU4SmtLUjkzODFILTVrYmltOTZMbTFlelIwb21rSHNqYVpvNlJ1RkNyckZzVjE1WmNaVWFkcVJGem1fMno2QQ?oc=5","date":"2022-02-14","type":"deal","source":"GlobeNewswire","summary":"Collegium to Acquire BioDelivery Sciences in an All-Cash Deal - GlobeNewswire","headline":"Collegium to Acquire BioDelivery Sciences in an All-Cash Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZVhRTDNVTkdNNkJTWFVfdUh2OXkwUU93UHFDVGptV1d5WjljTDZMaWcyYkJ4bnVXZkRlT1RSeGtfdzFTWFJrWWhnSWhEaHBvaE9kbGRlRURfMlFiVWRBRGE0TjFwQy1OaFFZcGNOT2t1Tk9zS2Y1YkRUZ29qNHZRTndfUldmNG1ZRTlSeGlwOENMOVB5UXBGcTVYVmFJZjQxNVFxTW5KNVJidw?oc=5","date":"2022-02-14","type":"deal","source":"The Business Journals","summary":"Raleigh drugmaker being acquired by competitor in $604M deal - The Business Journals","headline":"Raleigh drugmaker being acquired by competitor in $604M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE82cVlxQ0lsLW9KdEloSDN5UTRHTXdZSktSN0JqSi1ERVQzVXlLTHlnWnp0dE9kYVdkX3c0UEhXSVQ3OTdvWFRVWVM4SHZqeWFwbE5uelZod1MwUl9GUVhIbnMzSjYyZ1l2UjZqWngwLVRwV0duNjBKNzVR?oc=5","date":"2021-08-28","type":"pipeline","source":"Allied Market Research","summary":"Opioid Use Disorder Market Size, Share | Industry Growth - 2031 - Allied Market Research","headline":"Opioid Use Disorder Market Size, Share | Industry Growth - 2031","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-08-05","type":"pipeline","source":"Indian Pharma Post","summary":"Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences - Indian Pharma Post","headline":"Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxQTm1yWGJqUjRSNnZXcGw3U2xMRl9MRnBZdERNTUxMOE42dzBLV0FXZkpfRjhKYlc3bmZNejNEWnNPbmd6SGJUZGFOM0tJRU5yay12YXZyTmdiRm9BRmo1WWFsS2FZdDhKV0RjWEFxa1h4VGRERXVoVTJscU05RUo3aGthbFFaS1VvSll5WVhhWUQyRndRMWNVeVpsVURnNVFjaXZDLW1uNDBoTlFJZXdFZEFXN3lveF9uN2w4aFNvZVFKeHRlSzZfdVVMZjVHNngzTC03VVRJT2Rja0VWVTM4RGtsVFYtaGdYQmRPbDdqTlE2V2tfdEY3VERPc1NrTy1OZmIyd05BWFZSMkxqdUR2QU1mbWE?oc=5","date":"2017-08-23","type":"pipeline","source":"PR Newswire","summary":"BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman - PR Newswire","headline":"BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as V","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcVliWm9lOVJoOTlYWldxSWNPQzRwN0poZXIxeXlIV1VDMDFHZkxVVFdod1RMLVdyeFh0WDVtV1NIdEJ4ejcyVGdJUlhtNDBRbUt2SmdaTVY5Z3p1VGt1QjdqbW9qek5ReGplMEQxWUEyYzRWV1YxYWFPTTFQSUNEeFJRVU5HZ0tzLXg4?oc=5","date":"2016-12-08","type":"deal","source":"BioSpace","summary":"BioDelivery Reacquires License To BELBUCA From Endo Pharma - BioSpace","headline":"BioDelivery Reacquires License To BELBUCA From Endo Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPMTYxYVh1N01RQkh1RmxsdXBEbTJra2o1WHQ4UkRvWU5pTXR2MlFaejFaeWdaTmZDZEphczRXbndMQjJvUk9qOVlyUGdFaEVqTm1ScThFanphSmI4WXB6QXd5dU9SZW9tMENYUEFsb2FicjN4aEFRQndCa0ZXTUZKaEU4YVYyWTlH?oc=5","date":"2016-12-08","type":"pipeline","source":"BioPharma Dive","summary":"Endo chops sales force after ditching pain drug - BioPharma Dive","headline":"Endo chops sales force after ditching pain drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQUHh0d19LNFYtZlQzTGhsdnV3UG1JcEd1cGVYQkhUT19tOFFiendIaWJvT0tueXVQRGFJc3g2cjNUQ2w5WFE3bkVpUF9QUGZhSzFOWjFEeDhIcUFKRkZnMGNmVENfeENieno0Qm5FbEVlSzNpRWo4WkRBNktFSEVick9MTlFLdy1GX3FVLWJOWjhydHd6ajNhcDgxM2xKajNWQlQ4S3pTUGEwZTZaUXdzaQ?oc=5","date":"2015-05-19","type":"trial","source":"Fierce Pharma","summary":"Endo, BDSI get positive results from pivotal trial of pain-fighting buccal film - Fierce Pharma","headline":"Endo, BDSI get positive results from pivotal trial of pain-fighting buccal film","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxORGJrNVZoNUhJOTRmNnhteE5OQmUyNlBWNVpUeGUteGRNVnJLT0NGOUpvQmZyWFZfUldQbHpQOG9NWmMzRWVGZHAxNHVkX19uWXBvTTYxNGthV3Jxby1FWHhHcFpJeEZYWG1UWWs3VjV1SWd4aHRlV2RyVXA4eXNWcTF4bUxUMFpMYWJUSEpZVGk5bUtzaUt2cnFqTmU1TFpNLXd4b1pCOHA4cHlPQk5kSmVjbjJoemJYQ1NrMFA4a2dUbXdfMXVqdk9hRkFPazlUeUVyT0NsTDc2bEgxZTZLTzJ5VkZPWUFkbkxObENTalhONjR1N1FfT2x3?oc=5","date":"2010-05-27","type":"regulatory","source":"RTTNews","summary":"BioDelivery Sciences Enters Into License And Supply Agreement With Kunwha Pharma For BEMA Fentanyl In South Korea - Quick Facts - RTTNews","headline":"BioDelivery Sciences Enters Into License And Supply Agreement With Kunwha Pharma For BEMA Fentanyl In South Korea - Quic","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_1":2,"discontinued":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":61985000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":61985000,"period":"2017-12-31"},{"value":12510000,"period":"2017-12-31"},{"value":11253000,"period":"2017-09-30"},{"value":8744000,"period":"2017-06-30"},{"value":29478000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":0,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":84860000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":324596000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}